Core Viewpoint - Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Pharmaceuticals Group Biotherapy Technology Co., Ltd., has received approval from the National Medical Products Administration for clinical trials of its self-developed drug "B019" for the treatment of refractory systemic lupus erythematosus [1] Group 1 - B019 injection is a chimeric antigen receptor T-cell injection targeting CD19 and CD22, aimed at treating refractory systemic lupus erythematosus [1] - The project has accumulated research and development expenses of approximately 149,000 RMB for this new indication [1]

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * 证券代码：601607 证券简称：上海医药 编号：临 2025-075 （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司關於硫酸沙丁胺醇注射液通過仿製藥一致性評價的公 告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 中國上海，2025 年 7 月 29 日 於本公告日期，本公司的執行董事為楊秋華先生、沈波先生、李永忠先生及董明 先生；非執行董事為張文學先生；以及獨立非執行董事為顧朝陽先生、霍文遜 ...

关于硫酸沙丁胺醇注射液通过仿制药一致性评价的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，上海医药集团股份有限公司（以下简称"公司"）下属上海禾丰制药 有限公司（以下简称"上药禾丰"）的硫酸沙丁胺醇注射液（以下简称"该药品"） 收到国家药品监督管理局（以下简称"国家药监局"）颁发的《药品补充申请批 准通知书》（通知书编号：2025B03280），该药品通过仿制药质量和疗效一致 性评价。 一、该药品基本情况 药品名称：硫酸沙丁胺醇注射液 剂型：注射剂 规格：1ml：0.5mg（按 C13H21NO3计） 注册分类：化学药品 申请人：上海禾丰制药有限公司 药品批准文号：国药准字 H20258131 审批结论：本品通过仿制药质量和疗效一致性评价。 证券代码：601607 证券简称：上海医药 编号：临 2025-075 上海医药集团股份有限公司 二、该药品相关的信息 硫酸沙丁胺醇注射液主要用于治疗支气管哮喘或喘息型支气管炎等伴有支 气管痉挛的呼吸道疾病。2024 年 2 月，上药禾丰就该药品新增规格合并仿制药 一致 ...

Core Viewpoint - A total of 16 A-share listed companies disclosed their latest merger and acquisition announcements during the week of July 21 to July 27, with notable transactions including Huylin Ecological's plan to acquire a 49% stake in Wuhan Junheng, and the resumption of trading for its stock on July 28 [1][3]. Group 1: Company Announcements - Huylin Ecological announced on July 25 its intention to purchase a 49% stake in Wuhan Junheng, with its stock set to resume trading on July 28 [3]. - Western Gold announced on July 25 its plan to acquire 100% of Xinjiang Meisheng for 1.655 billion yuan [3]. - Guochuang High-tech announced on July 25 its plan to acquire 100% of Ningbo Guopei for 22.5 million yuan [3]. - Shanghai Pharmaceuticals announced on July 25 its intention to acquire a 10% stake in a financial company held by Shashi Dongtan [3]. - Heng Rui Medicine announced on July 25 its plan to acquire a 1.4587% stake in Chengdu Shengdi Medicine for 4.0144 million yuan [3]. - Yuanli Co. announced on July 24 its intention to purchase 100% of Tongsheng Co., with its stock set to resume trading [3]. - Angel Yeast announced on July 24 its plan to acquire a 55% stake in Zuitong Sugar Industry for 506 million yuan [3]. - Jinlong Co. announced on July 23 its intention to acquire a 29.32% stake in Zhisuang Company [3]. - Huayu Mining announced on July 23 its plan to acquire an 11% stake in Asia Pacific Mining for 300 million yuan [3]. - Titan Technology announced on July 23 its intention to acquire 100% of ASL for approximately 55.85 million yuan [3]. - GoerTek announced on July 22 its plan to acquire Mia Precision Technology Co. and Changhong Industrial Co. for approximately 10.4 billion Hong Kong dollars [3]. - Geer Software announced on July 22 its intention to acquire more than 51% of Weipin Zhiyuan, which owns an intelligent orchestration platform [3]. - Tianrun Industrial announced on July 22 its plan to acquire 100% of Shandong Altai for 13.5 million yuan [3]. - Hanyi Co. announced on July 22 its intention to acquire a 39% stake in Shanghai Pidong Cultural Media for 10.2 million yuan [3]. - ST Xifa announced on July 21 its plan to cash purchase a 50% stake in Lhasa Beer held by Carlsberg, which is expected to constitute a major asset restructuring [3]. - Beiding Co. announced on July 21 its intention to acquire 100% of Zhongshan Kairui for 156 million yuan [3].

Core Viewpoint - Shanghai Pharmaceuticals plans to acquire a 10% stake in Shanghai Shihua Group Financial Co., Ltd. for approximately RMB 143 million, increasing its ownership from 30% to 40% without changing the consolidation scope of the financial statements [1][2]. Group 1: Transaction Overview - The acquisition will be funded by the company's own capital and is classified as a related party transaction, but it does not constitute a major asset restructuring [2][6]. - The financial company has shown steady growth since its establishment in 2014, with cumulative cash dividends of approximately RMB 230 million since 2016 [2][16]. - The transaction is expected to enhance the company's control over significant decisions of the financial company and provide stable investment returns [2][16]. Group 2: Financial Information of the Target - The financial company has total assets of approximately RMB 1.17 billion and total liabilities of about RMB 1.03 billion, resulting in net assets of approximately RMB 143 million [8][9]. - The financial company reported operating income of approximately RMB 13 million and net profit of about RMB 6 million [8][9]. Group 3: Valuation and Pricing - The transaction price will be based on an evaluation report from a qualified asset appraisal agency, with the assessed value of the 10% stake being approximately RMB 143 million [9][11]. - The valuation methods used include the asset-based approach and market approach, with the asset-based approach being deemed more reflective of the company's market value [9][10]. Group 4: Approval and Compliance - The transaction requires internal approvals and regulatory filings, including approvals from state-owned asset supervision and financial regulatory authorities [12][15]. - The board of directors has approved the transaction, with related party director Yang Qiuhua abstaining from the vote [16].

证券代码：601607 证券简称：上海医药 公告编号：临2025-073 上海医药集团股份有限公司 第八届董事会第二十三次会议决议公告 详见本公司公告临 2025-072 号。 本议案已经过公司第八届董事会独立董事专门会议第九次会议审议通过，同 意提交董事会审议。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海医药集团股份有限公司（以下简称"本公司"）第八届董事会第二十三 次会议（以下简称"本次会议"）于 2025 年 7 月 25 日以通讯方式召开。本次会 议应到董事 9 名，实到董事 9 名，符合《中华人民共和国公司法》和本公司章程 关于董事会召开法定人数的规定。本次会议审议并通过了以下议案： 关联/连董事杨秋华先生主动回避该议案的表决，八位非关联/连董事全部投 票同意。 表决结果：赞成 8 票，反对 0 票，弃权 0 票 特此公告。 上海医药集团股份有限公司 董事会 二零二五年七月二十六日 同意公司以自有资金约人民币 1.43 亿元（以最终国资备案价格为准）收购 上海实业东滩投资开发（集团）有限公司持有的上海 ...

Major Events - Guotai Junan Asset Management will absorb Haitong Asset Management as approved by Guotai Haitong [1] - Shikong Technology's actual controller is planning a change in control, leading to continued suspension of trading [1] - Fushun Special Steel's Jincheng Shazhou intends to acquire 5% of the company's shares at 5.6 CNY per share [1] - Xibu Materials' Wang Libo resigned from the position of vice chairman due to job changes [1] - Yitian Intelligent plans to establish a private equity fund with a professional institution [1] Performance - Tapa Group reported a net profit of 435 million CNY for the first half of the year, a year-on-year increase of 92.47% [2] - Qilu Bank's net profit for the first half of the year was 2.734 billion CNY, up 16.48% year-on-year [2] - Western Mining's net profit for the first half of the year reached 1.869 billion CNY, a 15% increase year-on-year [2] - Funiang Co.'s net profit for the first half of the year was 1.337 billion CNY, reflecting a year-on-year growth of 12.48% [2] - China Duty Free Group reported a net profit of 2.6 billion CNY for the first half of the year, a year-on-year decrease of 20.81% [2] Shareholding Changes - Softcom Power's shareholder plans to transfer 3% of the company's shares through inquiry [2] - Hu Lixia, a shareholder of Guoguang Co., plans to reduce holdings by no more than 3% [3] - Taiyuan Heavy Industry's controlling shareholder plans to increase holdings by 80 million to 160 million CNY [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準 確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產 生或因依賴該等內容而引致之任何損失承擔任何責任。 (股份代碼: 02607) 關連交易 擬收購財務公司 10%股權 收購事項 董事會欣然宣佈，於 2025 年 7 月 25 日，本公司（買方）與上實東灘（賣方）擬訂立股份 轉讓協議，據此本公司擬收購而上實東灘擬出售財務公司 10%股權，代價為人民幣 143,335,577.71 元（以最終國資備案價格為准）。於本公告日期，財務公司分別由上海上 實、本公司、上實資產及上實東灘持有 40%、30%、20%及 10%股權。於收購事項完成後 ，財務公司將由本公司直接持有 40%股權。 上市規則的涵義 於本公告日期，上海上實為本公司之控股股東，上實東灘為上海上實之全資附屬公司。據 此，上實東灘因作為本公司控股股東之聯繫人而成為本公司之關連人士。因此，根據上市 規則第 14A 章，收購事項構成本公司之關連交易。 上海醫藥集團股份有限公司 Shanghai Pharmaceuticals Holding Co., L ...

香港交易及結算所有限公司和香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 上 海 醫 藥 集 團 股 份 有 限 公 司 Shanghai Pharmaceuticals Holding Co., Ltd. * （於中華人民共和國註冊成立的股份有限公司） （股份代碼：02607） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第 13.10B 條而作出。 茲載列上海醫藥集團股份有限公司（「本公司」）在上海證券交易所網站(http://www.sse.com.cn) 刊登的《上海醫藥集團股份有限公司第八屆董事會第二十三次會議決議公告》、《上海醫藥集 團股份有限公司關於 2019 年 A 股股票期權激勵計畫預留股票期權第三個行權期限制行權期 間的提示性公告》僅供參閱。 承董事會命 上海醫藥集團股份有限公司 楊秋華 董事長 证券代码：601607 证券简称：上海医药 公告编号：临2025-073 上海医药集团股份有限公司 第八届董事会第二十三次会议决议公告 本公司董事 ...

Corporate Announcements - Sanfeng Intelligent's director Chen Wei has been placed under investigation, but the company's operations remain normal and unaffected [3] - Shanghai Pharmaceuticals plans to acquire a 10% stake in Shanghai Shihua Group Financial Company for 143 million yuan, increasing its ownership from 30% to 40% [4] - Western Gold intends to acquire 100% of Xinjiang Meisheng Mining for 1.655 billion yuan, with a premium of 1421.66% over book value; the target company is expected to commence production in the second half of 2025 [5] - Hengrui Medicine plans to acquire approximately 1.46% of Chengdu Shengdi Pharmaceutical from minority shareholders for 40.144 million yuan, increasing its stake to 97.37% [6] - Dongshan Precision has approved an investment of up to 1 billion USD for a high-end printed circuit board project to meet long-term demand in emerging markets [7] - ST Wanfang and Rebecca have both received notices from the China Securities Regulatory Commission regarding investigations into information disclosure violations, but their operations remain normal [8][9] Financial Performance - China Duty Free Group reported a net profit of 2.6 billion yuan for the first half of 2025, a decrease of 20.81% year-on-year, with total revenue of 28.151 billion yuan, down 9.96% [13] - Digital Certification expects a loss of 80 to 96 million yuan for the first half of 2025, compared to a loss of 29.25 million yuan in the same period last year [14] - Western Mining reported a net profit of 1.869 billion yuan for the first half of 2025, an increase of 15% year-on-year, with total revenue of 31.619 billion yuan, up 27% [15] Major Contracts - ST Dongyi signed new orders worth 215 million yuan in the second quarter for its decoration business, with total uncompleted contracts amounting to 383 million yuan [17] - Guangshen Railway signed a cooperation agreement for the Guangzhou East Station renovation project, with a total investment of approximately 16.66 billion yuan [18] Shareholder Actions - Huajin Technology's employee stock ownership platform plans to reduce its stake by up to 4% within three months [20] - Liuyuan Group intends to repurchase shares worth between 100 million and 200 million yuan, with a maximum repurchase price of 25.7 yuan per share [22]